Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis

Pharmacogenomics J. 2017 Jan;17(1):84-91. doi: 10.1038/tpj.2015.85. Epub 2015 Dec 8.

Abstract

The aim of the study is the identification of genetic factors that influence the long-term response to interferon-β (IFNβ) (4-year follow-up). We performed a genome-wide association study in 337 IFNβ-treated Italian multiple sclerosis patients at the extreme of treatment response, and we meta-analyzed association effects, integrating results with pathway analysis, gene-expression profiling of IFNβ-stimulated peripheral blood mononuclear cells from 20 healthy controls (HC) and expression quantitative locus (eQTL) analyses. From meta-analysis, 43 markers were associated at P<10-4, and two of them (rs7298096 and rs4726460) pointed to two genes, NINJ2 and TBXAS1, that were significantly downregulated after IFNβ stimulation in HC (P=3.1 × 10-9 and 5.6 × 10-10). We also observed an eQTL effect for the allele associated with favorable treatment response (rs4726460A); moreover, TBXAS1 appeared downregulated upon IFNβ administration (β=-0.39; P=0.02). Finally, we found an enrichment of pathways related to inflammatory processes and presynaptic membrane, the latter with involvement of genes related to glutamatergic system (GRM3 and GRIK2), confirming its potential role in the response to IFNβ.

Publication types

  • Meta-Analysis

MeSH terms

  • Adolescent
  • Adult
  • Case-Control Studies
  • Cell Adhesion Molecules, Neuronal / genetics
  • Female
  • Gene Expression Profiling
  • Genome-Wide Association Study
  • Genotype
  • GluK2 Kainate Receptor
  • Humans
  • Immunologic Factors / adverse effects
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / adverse effects
  • Interferon-beta / therapeutic use*
  • Italy
  • Male
  • Middle Aged
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / genetics
  • Multiple Sclerosis / immunology
  • Pharmacogenetics*
  • Pharmacogenomic Testing / methods
  • Pharmacogenomic Variants*
  • Phenotype
  • Polymorphism, Single Nucleotide*
  • Quantitative Trait Loci
  • Receptors, Kainic Acid / genetics
  • Receptors, Metabotropic Glutamate / genetics
  • Time Factors
  • Treatment Outcome
  • Young Adult

Substances

  • Cell Adhesion Molecules, Neuronal
  • Immunologic Factors
  • NINJ2 protein, human
  • Receptors, Kainic Acid
  • Receptors, Metabotropic Glutamate
  • metabotropic glutamate receptor 3
  • Interferon-beta